<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217177</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001C24128</org_study_id>
    <nct_id>NCT01217177</nct_id>
  </id_info>
  <brief_title>A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer</brief_title>
  <acronym>PHOENIX I</acronym>
  <official_title>A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The cervix cancer is the second malignant neoplasia more common between women. The combined&#xD;
      treatment involving chemotherapy and radiotherapy was defined as the standard. This study&#xD;
      will evaluate the safety, toxicity and maximal tolerated dose (MTD) of everolimus in&#xD;
      association with cisplatin and pelvic radiotherapy, in patients with squamous cells carcinoma&#xD;
      of uterine cervix, in stages IIB and IIIB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0.</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The objective response rate will be evaluated according to clinical/gynecological examination and inconformity with the RECIST criteria (Response Evaluation Criteria in Solid Tumors, version 1.1)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Locally Advanced Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>2.5 mg everolimus + radiotherapy + cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0 mg everolimus + radiotherapy + cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg everolimus + radiotherapy + cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <arm_group_label>10 mg everolimus + radiotherapy + cisplatin</arm_group_label>
    <arm_group_label>2.5 mg everolimus + radiotherapy + cisplatin</arm_group_label>
    <arm_group_label>5.0 mg everolimus + radiotherapy + cisplatin</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG performance of 0, 1 or 2.&#xD;
&#xD;
          2. Evidence of measurable disease of unidimensional form.&#xD;
&#xD;
          3. Epidermoid carcinoma confirmed by histological examination of cervix, stages IIB to&#xD;
             IIIB (according to clinical and radiological evaluation), without previous treatment.&#xD;
             Absence of positive paraaortic lymph nodes at PET (Positron Emission Tomography).&#xD;
&#xD;
          4. Adequate function of organ, according to following criteria:&#xD;
&#xD;
               1. Serum levels of aspartate aminotransferase (ASAT/AAT/AST) and alanine&#xD;
                  aminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal)&#xD;
&#xD;
               2. Total serum bilirubin ≤1.5 ULN&#xD;
&#xD;
               3. Absolute neutrophils counting ≥1.500/mm3&#xD;
&#xD;
               4. Platelet counting ≥100.000/mm3&#xD;
&#xD;
               5. Hemoglobin ≥10.0 g/dL&#xD;
&#xD;
               6. Serum calcium ≤12.0 mg/dL&#xD;
&#xD;
               7. Serum creatinine ≤1.5 x ULN and estimate creatinine clearance (Cockroft-Gault)&#xD;
                  ≥60 mL/min&#xD;
&#xD;
               8. Prothrombin time ≤1.5 x ULN Obs.: The serum levels of potassium, magnesium,&#xD;
                  sodium and calcium outside normality range should be corrected before the&#xD;
                  administration of the first dose of investigational product.&#xD;
&#xD;
          5. Patients with at least one measurable lesion in the baseline period, according to&#xD;
             criteria RECIST, version 1.1.&#xD;
&#xD;
          6. Adequate lipid profile: total cholesterol &lt;300 mg/dL and triglycerides &lt;200 mg/dL.&#xD;
&#xD;
          7. Willingness to follow the treatment plan, scheduled visits, laboratory and&#xD;
             radiological examinations, as well as other procedures.&#xD;
&#xD;
          8. Signed and dated informed consent form, indicating that the patient (or his/her&#xD;
             representative) has received information about all relevant study aspects, before&#xD;
             his/her inclusion.&#xD;
&#xD;
        Women with possibility to become pregnant should present a negative serum examination for&#xD;
        pregnancy, done within the period of 7 days before the administration of study treatment;&#xD;
        and should be willing to use a contraceptive method along the entire study, and for 3&#xD;
        months after the last administration of investigational drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery &lt;4 weeks before study treatment starting.&#xD;
&#xD;
          2. Any malignant neoplasia in the last 5 years, except for adequately treated melanoma&#xD;
             skin cancer.&#xD;
&#xD;
          3. Metastases in the initial diagnostic evaluation [thorax and abdomen computerized&#xD;
             tomography (with contrast), pelvis magnetic resonance and PET scanning].&#xD;
&#xD;
          4. Occurrence of some of the following events, during the period of 12 months previously&#xD;
             to study medication administration: unstable angina pectoris, symptomatic congestive&#xD;
             heart failure (II, III, IV of NYHA), myocardium infarction, severe uncontrolled&#xD;
             cardiac arrhythmia, cerebrovascular accident.&#xD;
&#xD;
          5. Positive serology for HIV infection.&#xD;
&#xD;
          6. Patients with positive examinations for hepatitis B (HBsAg, anti-HBs without previous&#xD;
             vaccination against HBV and anti-HBc) and hepatitis C (HCV RNA detectable by PCR).&#xD;
&#xD;
          7. Any psychologic, familial, social or geographic problem that could embarrass the&#xD;
             adhesion to protocol and study scheme.&#xD;
&#xD;
          8. Patients using other agents under investigation or receiving investigational&#xD;
             medications ≤4 weeks before the study treatment starting.&#xD;
&#xD;
          9. Patients presenting some severe and/or uncontrolled medical problem, or other&#xD;
             disturbances that could affect their participation in the study, such as, for&#xD;
             instance:&#xD;
&#xD;
               -  Unstable angina pectoris, symptomatic congestive heart failure (II, III, IV of&#xD;
                  NYHA), myocardial infarction ≤12 months before the first administration of study&#xD;
                  medication, severe uncontrolled cardiac arrhythmia, cerebrovascular accident ≤12&#xD;
                  months before the starting of study medication administration;&#xD;
&#xD;
               -  Severely compromised pulmonary function defined by spirometry with 50% of&#xD;
                  anticipated normal value or decompensated pulmonary disease.&#xD;
&#xD;
               -  Uncontrolled diabetes satisfactorily defined by a fast glycemia result &gt;2.0 x&#xD;
                  ULN;&#xD;
&#xD;
               -  Any active or uncontrolled disease/infection (acute or chronic) compromising the&#xD;
                  patient evaluation capability or impeding him/her to complete the study.&#xD;
&#xD;
               -  Hepatic disease with cirrhosis, decompensated hepatic disease, active chronic&#xD;
                  hepatitis, or persistent chronic hepatitis.&#xD;
&#xD;
               -  Compromising of gastrointestinal (GI) function, or GI disease that could&#xD;
                  significantly alter the everolimus absorption.&#xD;
&#xD;
         10. Patients unwilling or unable to accomplish the protocol requirements.&#xD;
&#xD;
         11. Hypersensitivity to everolimus or any of its excipients, or to other rapamycins (for&#xD;
             instance: sirolimus, temsirolimus).&#xD;
&#xD;
         12. Patients receiving systemic immunosuppressive agents chronically. Inhaling or topic&#xD;
             corticosteroids are acceptable. The patients should be receiving stable chronic (not&#xD;
             increased within the last month) doses of corticosteroids, with the maximal dose&#xD;
             corresponding to 20 mg de prednisone or 10 mg of dexamethasone per day.&#xD;
&#xD;
        Pregnant (that is, having positive examination for beta human chorionic gonadotropin) or&#xD;
        lactating women.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer,</keyword>
  <keyword>radiotherapy,</keyword>
  <keyword>chemotherapy,</keyword>
  <keyword>rad001,</keyword>
  <keyword>everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

